Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in San Francisco, California

This page shows live ClinicalTrials.gov search results for San Francisco, California, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 3:32 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
5126
Shown on this page
12
Current sort
Recently updated
Location scope
San Francisco, CA
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within San Francisco, California. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 133–144 of 5,126 matching trials in San Francisco, CA.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Institutions in San Francisco

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search
Recruiting No phase listed Observational

Universal Rare Gene Study: A Registry and Natural History Study of Retinal Dystrophies Associated With Rare Disease-Causing Genetic Variants

NCT05589714
View directory record Official record
Conditions
Inherited Retinal Degeneration, Retinitis Pigmentosa
Interventions
Not listed
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
4 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
19
States / cities
Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Nov 4, 2026, 3:32 PM EST
Active, not recruiting No phase listed Observational

Rate of Progression in USH2A-related Retinal Degeneration

NCT03146078
View directory record Official record
Conditions
Usher Syndrome, Type 2A, Retinitis Pigmentosa 39
Interventions
Not listed
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
8 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2029
U.S. locations
9
States / cities
San Francisco, California • Gainesville, Florida • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Nov 4, 2026, 3:32 PM EST
Active, not recruiting Phase 3 Interventional

EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

NCT06531824
View directory record Official record
Conditions
Kidney Disease, Chronic
Interventions
BI 690517, Placebo matching BI 690517, Empagliflozin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
8,371 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
53
States / cities
Huntsville, Alabama • Surprise, Arizona • Beverly Hills, California + 46 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 4, 2026, 3:32 PM EST
No Longer Available No phase listed Expanded access

Compassionate Use of Concizumab if You Have Haemophilia

NCT04921956
View directory record Official record
Conditions
Congenital Haemophilia
Interventions
Concizumab
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
23
States / cities
Los Angeles, California • San Francisco, California • Hartford, Connecticut + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 4, 2026, 3:32 PM EST
Completed Phase 3 Interventional Results available

Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young Children

NCT03859700
View directory record Official record
Conditions
Peanut Allergy
Interventions
DBV712 250 mcg
Biological
Lead sponsor
DBV Technologies
Industry
Eligibility
2 Years to 5 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
26
States / cities
Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 4, 2026, 3:32 PM EST
Recruiting Phase 2 Interventional

A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma

NCT07428616
View directory record Official record
Conditions
Meningioma
Interventions
Zanzalintinib
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
20
States / cities
Birmingham, Alabama • Phoenix, Arizona • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 4, 2026, 3:32 PM EST
Active, not recruiting Phase 2Phase 3 Interventional

A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1

NCT04534205
View directory record Official record
Conditions
Unresectable Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer
Interventions
BNT113, Pembrolizumab
Biological
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
15
States / cities
Los Angeles, California • Palo Alto, California • New Haven, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 4, 2026, 3:32 PM EST
Active, not recruiting Phase 3 Interventional

A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis

NCT05269004
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ocrelizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
48
States / cities
Phoenix, Arizona • Laguna Hills, California • Palo Alto, California + 39 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 4, 2026, 3:32 PM EST
Recruiting Phase 3 Interventional

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

NCT03418961
View directory record Official record
Conditions
Cardiotoxicity, HER2/Neu Positive, Metastatic Malignant Neoplasm in the Brain, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
Interventions
Carvedilol, Laboratory Biomarker Analysis, Patient Observation
Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
491 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2031
U.S. locations
577
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Hot Springs, Arkansas + 375 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 4, 2026, 3:32 PM EST
Recruiting Phase 3 Interventional

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

NCT06424288
View directory record Official record
Conditions
Heart Failure
Interventions
vicadrostat, empagliflozin, placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
6,712 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
94
States / cities
Mobile, Alabama • Chula Vista, California • Orange, California + 81 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 4, 2026, 3:32 PM EST
Recruiting Phase 3 Interventional

EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

NCT07064473
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Hypertension, Cardiovascular Diseases
Interventions
Vicadrostat, Empagliflozin, Placebo matching Vicadrostat
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
11,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
208
States / cities
Anniston, Alabama • Fairhope, Alabama • Guntersville, Alabama + 171 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 4, 2026, 3:32 PM EST
Recruiting Phase 3 Interventional

The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

NCT06872892
View directory record Official record
Conditions
Bronchiectasis
Interventions
BI 1291583, Placebo matching BI 1291583
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
12 Years and older
Enrollment
1,755 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
78
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 4, 2026, 3:32 PM EST